CA-SYNTERACTHCR
SynteractHCR Holdings Corporation today announced that Steve Powell has been appointed chief executive officer, effective July 10, 2017. Mr. Powell succeeds Wendel Barr, who departs SynteractHCR after six years as CEO. A portfolio company of Amulet Capital Partners, LP, SynteractHCR is a leading, international contract research organization (CRO) focused on Phase I-IV clinical trials for innovative biopharma clients in the U.S., Europe and Asia.
Mr. Powell has more than 25 years of executive leadership experience in both the CRO and pharma/biotech industries. Drawing on this strong base of expertise, he will direct the overall company strategy, positioning, processes and performance.
“Steve Powell is a respected leader who has built an impressive track record of delivering results, both strategically and operationally, with deep involvement across all facets of late stage clinical research,” said Ramsey Frank, partner and co-founder of Amulet. “As large and mid-sized CROs consolidate, SynteractHCR has a unique opportunity to become a dominant CRO focused on the needs of highly innovative, pharma and biotech customers. Under Steve’s leadership, SynteractHCR will be in position to take full advantage of this opportunity.”
Mr. Powell joins SynteractHCR from ERT, having come to ERT through its acquisition of Exco InTouch in December 2016. As president and COO of Exco InTouch, a leading provider of patient engagement, data capture and digital health solutions, Mr. Powell managed all aspects of operational delivery and technology development. While at ERT, he managed a leading product line, which provided an integrated data and analytics platform. Prior to Exco InTouch/ERT, Mr. Powell served as executive vice president, Clinical Informatics and Late Phase Services at PRA Health Sciences for over eight years where he was instrumental in that company’s global expansion from 2,000 to more than 10,000 employees. Prior to joining PRA in 2006, he held several leadership positions across the health care, technology and CRO industries.
Mr. Frank added, “We want to thank Wendel Barr for his tremendous contributions to SynteractHCR, and for playing a key role in shaping the company over the last six years. The company has benefited greatly from his leadership."
Mr. Powell noted that SynteractHCR is well positioned to capitalize on changes in the industry, with its ability to provide flexible, high quality service and strategic guidance to address the needs of pharma and biotech customers: “I am excited to join SynteractHCR at this pivotal time in its growth. The company is a leading CRO with global scale, excellent momentum, and a strong commitment to operational excellence for its customers in all phases of clinical development. I'm looking forward to working with our talented team and with our customers, as well as with Amulet, to take SynteractHCR to the next level.”
About SynteractHCR
SynteractHCR is a full-service international contract research organization (CRO) with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development . SynteractHCR has conducted Phase I-IV studies on six continents and 60 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, immunotherapy, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “Shared Work – Shared Vision ” philosophy and core values, SynteractHCR provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data to help bring tomorrow’s treatments to patients.
About Amulet Capital Partners, LP
Amulet Capital Partners , LP is a middle-market private equity investment firm based in Greenwich, CT, focused exclusively on the healthcare sector. Amulet seeks to achieve long-term capital appreciation through privately negotiated investments in companies. Amulet Capital Partners focuses on those segments it believes have the most attractive long-term fundamentals with a target investment size generally between $25 million to $150 million. Amulet Capital Partners' investment team has approximately 40 years of private equity experience. For additional information, please visit www.amuletcapital.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20170717005214/en/
Contact:
Contact for SynteractHCR:
Beth Walsh, 760-230-2424
beth@clearpointagency.com
or
Contact
for Amulet Capital Partners:
Melissa Sheer, 917-690-2199
melissa@kentplacellc.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agendia to Present FLEX Study Data on Impact of BluePrint® at ESMO Breast Cancer 20256.5.2025 08:00:00 CEST | Press release
Real-world analysis shows BluePrint® identifies chemotherapy-sensitive Basal-type tumors among MammaPrint® High Risk HR+ HER2- breast cancers, supporting more personalized treatment strategies Agendia®, Inc., today announced that new data from its ongoing FLEX Study will be presented at the upcoming ESMO BreastCancer 2025 congress taking place May 14-17 in both Munich, Germany and virtually. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250505212759/en/ The FLEX Study (NCT03053193) is a prospective real-world evidence, observational breast cancer study designed to correlate whole transcriptome gene expression in early-stage breast cancer with clinical outcomes, and to evaluate how genomic insights can inform treatment decisions in early-stage breast cancer. In this analysis, researchers examined the impact of BluePrint, Agendia’s 80-gene molecular subtyping assay, on pathological complete response (pCR) rates and chemothera
Owkin Launches K Navigator, a Ground-breaking Agentic Co-pilot to Speed up Breakthroughs in Biomedical Research by 20x6.5.2025 06:15:00 CEST | Press release
K Navigator increases researcher productivity by 20x¹, accelerating biomedical breakthroughs and outperforming leading generalist LLMs Analyzes and visualizes multimodal patient data, plus exclusive access to MOSAIC Window, a subset of the world’s largest spatial omics dataset in oncology Built by biologists, for biologists. Free to use for academic researchers.² Owkin, a leading agentic AI company, has launched K Navigator, an AI-powered research co-pilot designed to revolutionize biomedical science. K Navigator is an agentic playground where researchers can explore, refine, and validate hypotheses, accelerating the quality and pace of their discoveries. With K Navigator, Owkin moves closer to its vision of developing the world’s first Biological Artificial Superintelligence (BASI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250505282917/en/ K Navigator home screen. A single natural language interface - K Navigator enab
NIKE, Inc. Announces Senior Leadership Changes to Accelerate Growth and Drive Win Now Action Plan5.5.2025 22:15:00 CEST | Press release
Amy Montagne Becomes President, NikePhil McCartney Becomes EVP, Chief Innovation, Design & Product OfficerNicole Graham Becomes EVP, Chief Marketing OfficerTom Clarke Becomes Chief Growth Initiatives OfficerHeidi O’Neill to Retire NIKE, Inc. (NYSE:NKE) announced a series of strategic changes to its Senior Leadership Team (SLT), elevating experienced leaders to accelerate progress against its Win Now action plan to position the company for future growth. Elliott Hill, President and CEO, NIKE, Inc. and Heidi O’Neill, President of Consumer, Product, and Brand, have decided the Consumer, Product, and Brand leadership will now be divided into three distinct areas: Consumer and Sport, Marketing, and Product Creation, inclusive of Innovation and Design. These roles will now report directly to Hill. As a result of these changes O’Neill has decided to retire from Nike after 26 years. She will continue to serve in an advisory capacity until September 2025. “For nearly three decades, Heidi has be
LR Health & Beauty Once Again Demonstrates Its Expertise in Aloe Vera5.5.2025 16:24:00 CEST | Press release
The social commerce company develops a unique combination of Aloe Vera Gel and fermented Aloe LR Health & Beauty has been synonymous with the best Aloe Vera quality on the market for over 20 years, and continuously invests in new product innovations to take full advantage of the plant's range of beneficial properties. The majority of the over 60 products are developed and produced directly at the company headquarters in Ahlen. LR has now made a decisive breakthrough in skin care cosmetics with its unique combination of pure Aloe Vera leaf gel and fermented Aloe Vera. The care products with the highest Aloe Vera content therefore not only work in the upper and middle layers of the skin, but also unleash the full potential of Aloe Vera in the deeper layers. The effectiveness of this LR Aloe Via Magic Power Duo has been confirmed by the dermatological institute, Dermatest. All the products tested based on a combination of Aloe Vera Gel and fermented Aloe were awarded the 5-star "very good
MultiBank Group Signs Strategic Partnership With MAG to Tokenize $3 Billion Real Estate Assets5.5.2025 16:09:00 CEST | Press release
The largest tokenization initiative of its kind comes ahead of the $MBG token launch, paving the way for regulated digital access to prime property assets MultiBank Group, the world’s largest financial derivatives institution based in Dubai has signed a historic $3 billion tokenization agreement with MAG, the leading real estate developer in the UAE, and Mavryk, a leading blockchain innovator — marking the largest real-world asset (RWA) tokenization initiative globally to date. The initiative highlights the imminent launch of $MBG, the utility token at the core of MultiBank’s next-generation digital finance ecosystem. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250505317631/en/ MultiBank Group Signs Strategic Partnership With MAG to Tokenize $3 Billion Real Estate Assets The partnership will bring MAG’s high-value real estate developments — The Ritz-Carlton Residences, Dubai, Creekside, which is part of the Keturah Resort
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom